Clinical trials
Phase 1 Leukemia, B-Cell trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Active, not recruiting | 6 |
| Recruiting | 3 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Baylor College of Medicine | 4 |
| Memgen, LLC | 3 |
| Celgene | 2 |
| National Cancer Institute (NCI) | 2 |
| Pharmacyclics LLC. | 2 |
| AbbVie | 1 |
| AstraZeneca | 1 |
| Athenex, Inc. | 1 |
| Celgene Corporation | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, B-Cell | 31 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 15 |
| Lymphoma, B-Cell | 10 |
| Lymphoma, Non-Hodgkin | 10 |
| Leukemia | 8 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 |
| Recurrence | 6 |
| Burkitt Lymphoma | 4 |
| Lymphoma | 4 |
| Lymphoma, B-Cell, Marginal Zone | 4 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.